Benefits of omega-3 fatty acid dietary supplementation on health-related quality of life in patients with meibomian gland dysfunction
Authors Oleñik A, Mahillo-Fernández I, Alejandre-Alba N, Fernández-Sanz G, Pérez M, Luxan S, Quintana S, de Carneros Llorente AM, García-Sandoval B, Jiménez-Alfaro I
Received 14 February 2014
Accepted for publication 20 March 2014
Published 30 April 2014 Volume 2014:8 Pages 831—836
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 4
Andrea Oleñik, Ignacio Mahillo-Fernández, Nicolás Alejandre-Alba, Guillermo Fernández-Sanz, María Alarcón Pérez, Sol Luxan, Silvia Quintana, Alfonso Martínez de Carneros Llorente, Blanca García-Sandoval, Ignacio Jiménez-Alfaro
Department of Ophthalmology, Fundación Jiménez Díaz, Madrid, Spain
Background: We assessed the impact of a dietary supplement based on the combination of omega-3 essential fatty acids and antioxidants on health-related quality of life in patients with meibomian gland dysfunction (MGD).
Methods: Patients of either sex (aged 18–85 years) diagnosed with MGD according to criteria identified at a 2011 International Workshop on Meibomian Gland Dysfunction participated in this randomized, double-masked, placebo-controlled study. Group A patients (controls) received an oral placebo supplement and group B patients received the oral study supplement (Brudysec® 1.5 g; Brudy Laboratories, Barcelona, Spain). At baseline and at 3-month follow-up, the patients completed the 36-Item Short Form Health Survey questionnaire using a Spanish validated version. The Physical (PCS) and Mental (MCS) Component Summary scores were the main outcome variables.
Results: A total of 61 patients completed the study (group A, n=31; group B, n=30). There were no significant differences in PCS and MCS scores at baseline between the two study groups, but after 3 months of treatment, significantly higher mean PCS and MSC scores were observed in patients treated with the active omega-3 dietary supplement as compared with controls (mean [standard deviation] PCS score 53.33±5.57 versus 47.46±7.31, P=0.008; mean MCS score 54.60±5.64 versus 47.80±8.45, P=0.0005). Moreover, mean differences between values at 3 months as compared with baseline were statistically significant for patients in group B (PCS score 7.14±5.81, 95% confidence interval 4.97–9.31, P=0.000; MCS score 5.96±7.64, 95% confidence interval 3.10–8.81, P=0.0002), whereas mean differences in patients assigned to group A were not statistically significant.
Conclusion: Dietary supplementation with a combination of omega-3 essential fatty acids and antioxidants had a significant beneficial effect on HRQoL (health-related quality of life) in patients with MGD.
Keywords: antioxidants, Brudysec®, nutraceuticals, polyunsaturated fatty acids
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]